The first report assessed the photosensitivity side effect of many kinase inhibitors, including crizotinib, on K562 (a BCR-ABL+ CML cell line) by combining the CETSA method with multiplexed quantitative mass spectrometry (MS) [84]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.